Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Bauer, Monica Brown, R. Cress, C. Parise, V. Caggiano (2007)
Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 109
Bhawna Sirohi, M. Arnedos, Sanjay Popat, Stanley Ashley, A. Nerurkar, G. Walsh, S.R.D. Johnston, I. Smith (2008)
Platinum-based chemotherapy in triple-negative breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 19 11
Q. Zeng, Zhong Yang, Yong-Jing Gao, Huaiping Yuan, K. Cui, Ying Shi, Hongyun Wang, Xudong Huang, Stephen Wong, Yaming Wang, S. Kesari, R. Ji, Xiaoyin Xu (2010)
Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study.European journal of cancer, 46 6
D. Miles, A. Chan, L. Dirix, J. Cortés, X. Pivot, P. Tomczak, T. Delozier, J. Sohn, L. Provencher, F. Puglisi, N. Harbeck, G. Steger, A. Schneeweiss, A. Wardley, A. Chlistalla, G. Romieu (2010)
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 20
F. André, S. Delaloge, J. Soria (2011)
Biology-driven phase II trials: what is the optimal model for molecular selection?Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 10
S. Ashwell, S. Zabludoff (2008)
DNA Damage Detection and Repair Pathways—Recent Advances with Inhibitors of Checkpoint Kinases in Cancer TherapyClinical Cancer Research, 14
G. Ferretti, A. Felici, F. Cognetti (2008)
HER2 and response to paclitaxel in node-positive breast cancer.The New England journal of medicine, 358 2
T. Tursz, F. André, V. Lazar, L. Lacroix, J. Soria (2011)
Implications of personalized medicine—perspective from a cancer centerNature Reviews Clinical Oncology, 8
J. Baselga, H. Roché, F. Costa, J. Segalla, H. Pinczowski, E. Ciruelos, S. Filho, P. Gómez, B. Eyll (2009)
SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).Cancer Research, 69
M. Cheang, S. Chia, D. Tu, S. Jiang, L. Shepherd, K. Pritchard, T. Nielsen (2009)
Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbé, J. Baurain, A. Testori, J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, W. Miller, P. Gascón, M. Lotem, K. Harmankaya, R. Ibrahim, S. Francis, Tai-Tsang Chen, R. Humphrey, A. Hoos, J. Wolchok (2011)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.The New England journal of medicine, 364 26
G. Pristauz, E. Petru, E. Stacher, J. Geigl, T. Schwarzbraun, O. Tsybrovskyy, R. Winter, F. Moinfar (2010)
Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutationsHistopathology, 57
D. Matthews, Michael Yakes, Jason Chen, M. Tadano, L. Bornheim, D. Clary, A. Tai, J. Wagner, N. Miller, Y. Kim, Scott Robertson, Louis Murray, L. Karnitz (2007)
Pharmacological Abrogation of S-Phase Checkpoint Enhances the Anti-Tumor Activity of Gemcitabine In VivoCell Cycle, 6
H. Bear, G. Tang, P. Rastogi, C. Geyer, A. Robidoux, J. Atkins, Luis Baez-Diaz, A. Brufsky, R. Mehta, L. Fehrenbacher, J. Young, F. Senecal, R. Gaur, R. Margolese, P. Adams, H. Gross, J. Costantino, S. Swain, E. Mamounas, N. Wolmark (2012)
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.The New England journal of medicine, 366 4
N. Lin, E. Claus, J. Sohl, A. Razzak, A. Arnaout, E. Winer (2008)
Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancerCancer, 113
H. Burstein, A. Elias, H. Rugo, M. Cobleigh, A. Wolff, P. Eisenberg, M. Lehman, B. Adams, C. Bello, S. Deprimo, C. Baum, K. Miller (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 11
Paula Ryan, N. Tung, S. Isakoff, Mehra Golshan, Andrea Richardson, A. Corben, Barbara Smith, R. Gelman, E. Winer, Judy Garber (2016)
Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
C. Perou (2010)
Molecular stratification of triple-negative breast cancers.The oncologist, 15 Suppl 5
N. Turner, Maryou Lambros, H. Horlings, A. Pearson, R. Sharpe, R. Natrajan, F. Geyer, Marieke Kouwenhove, B. Kreike, A. Mackay, A. Ashworth, M. Vijver, J. Reis-Filho (2009)
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsOncogene, 29
R. Dent, G. Lindeman, M. Clemons, H. Wildiers, A. Chan, N. Mccarthy, C. Singer, E. Lowe, K. Kemsley, J. Carmichael (2010)
Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.Journal of Clinical Oncology, 28
Miguel Martín, M. Seguí, A. Antón, A. Ruíz, M. Ramos, E. Adrover, I. Aranda, Á. Rodríguez-Lescure, R. Grosse, L. Calvo, A. Barnadas, D. Isla, P. Prado, M. Borrego, J. Zaluski, Á. Arcusa, M. Muñoz, J. Vega, J. Mel, B. Munárriz, C. Llorca, C. Jara, E. Alba, J. Florián, Junfang Li, J. García-Asenjo, A. Sáez, M. Ríos, S. Almenar, G. Peiró, A. Lluch (2010)
Adjuvant docetaxel for high-risk, node-negative breast cancer.The New England journal of medicine, 363 23
S. Kimbung, E. Biskup, Ida Johansson, Kristina Aaltonen, Astrid Ottosson-Wadlund, Sofia Gruvberger-Saal, H. Cunliffe, B. Fadeel, N. Loman, P. Berglund, I. Hedenfalk (2012)
Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.Cancer letters, 319 2
José Baselga (2010)
Treatment of HER2-overexpressing breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 7
J. Huober, G. Minckwitz, C. Denkert, H. Tesch, E. Weiss, D. Zahm, A. Belau, F. Khandan, M. Hauschild, C. Thomssen, B. Högel, S. Darb-Esfahani, K. Mehta, S. Loibl (2010)
Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio studyBreast Cancer Research and Treatment, 124
G. Viale, N. Rotmensz, P. Maisonneuve, L. Bottiglieri, E. Montagna, A. Luini, P. Veronesi, M. Intra, R. Torrisi, A. Cardillo, E. Campagnoli, A. Goldhirsch, M. Colleoni (2009)
Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivityBreast Cancer Research and Treatment, 116
J. Gurtler, L. Goldstein, S. Delprete, S. Tjulandin, V. Semiglazov, L. Sternås, B. Michiels, E. Gilles (2005)
Trabectedin in third line breast cancer: A multicenter, randomized, phase II study comparing two administration regimensJournal of Clinical Oncology, 23
K. Gelmon, H. Hirte, A. Robidoux, K. Tonkin, M. Tischkowitz, K. Swenerton, D. Huntsman, J. Carmichael, E. Macpherson, A. Oza (2010)
Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer.Journal of Clinical Oncology, 28
A. Reid, G. Attard, D. Danila, N. Oommen, D. Olmos, P. Fong, L. Molife, J. Hunt, C. Messiou, C. Parker, D. Dearnaley, J. Swennenhuis, L. Terstappen, Gloria Lee, T. Kheoh, A. Molina, C. Ryan, E. Small, H. Scher, J. Bono (2010)
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 9
(2009)
: high incidence of central nervous system metastases
Emma Bolderson, D. Richard, Bin-Bing Zhou, K. Khanna (2009)
Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break RepairClinical Cancer Research, 15
A. Gennari, M. Sormani, P. Pronzato, M. Puntoni, M. Colozza, Ulrich Pfeffer, P. Bruzzi (2008)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.Journal of the National Cancer Institute, 100 1
(2007)
Randomized phase II study of weekly irinotecan
R. Finn, J. Dering, C. Ginther, Cindy Wilson, Padraic Glaspy, N. Tchekmedyian, D. Slamon (2007)
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitroBreast Cancer Research and Treatment, 105
R. Dent, M. Trudeau, K. Pritchard, W. Hanna, H. Kahn, C. Sawka, L. Lickley, E. Rawlinson, P. Sun, S. Narod (2007)
Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 13
Chris Jones, A. Mackay, A. Grigoriadis, A. Cossu, J. Reis-Filho, L. Fulford, T. Dexter, S. Davies, K. Bulmer, E. Ford, S. Parry, M. Budroni, G. Palmieri, A. Neville, M. O'hare, S. Lakhani (2004)
Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer.Cancer research, 64 9
C. Marchiò, B. Weigelt, J. Reis-Filho (2010)
Adenoid cystic carcinomas of the breast and salivary glands (or ‘The strange case of Dr Jekyll and Mr Hyde’ of exocrine gland carcinomas)Journal of Clinical Pathology, 63
T. Nielsen, Forrest Hsu, Kristin Jensen, M. Cheang, G. Karaca, Zhiyuan Hu, T. Hernandez-Boussard, C. Livasy, D. Cowan, L. Dressler, L. Akslen, J. Ragaz, A. Gown, C. Gilks, M. Rijn, C. Perou (2004)
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaClinical Cancer Research, 10
D. Tan, C. Marchiò, Robin Jones, K. Savage, I. Smith, M. Dowsett, J. Reis-Filho (2008)
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patientsBreast Cancer Research and Treatment, 111
D. Voduc, T. Nielsen, M. Cheang, W. Foulkes (2008)
The combination of high cyclin E and Skp2 expression in breast cancer is associated with a poor prognosis and the basal phenotype.Human pathology, 39 10
H. Joensuu, P. Kellokumpu-Lehtinen, R. Huovinen, A. Jukkola-Vuorinen, M. Tanner, R. Kokko, J. Ahlgren, P. Auvinen, P. Bono, H. Lindman (2010)
Abstract S4-1: FinXX Final 5-Year Analysis: Results of the Randomised, Open-Label, Phase III Trial in Medium-to-High Risk Early Breast CancerCancer Research, 70
E. Rakha, I. Ellis (2009)
Triple‐negative/basal‐like breast cancer: reviewPathology, 41
Iwan Beuvink, A. Boulay, S. Fumagalli, Frédéric Zilbermann, S. Ruetz, T. O'reilly, F. Natt, Jonathan Hall, H. Lane, G. Thomas (2005)
The mTOR Inhibitor RAD 001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p 21 Translation
M. Laé, P. Fréneaux, X. Sastre-Garau, O. Chouchane, B. Sigal‐Zafrani, A. Vincent-Salomon (2009)
Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrumModern Pathology, 22
H. Rugo, H. Roché, E. Thomas, K. Blackwell, H. Chung, G. Lerzo, La Volles, V. Poulart, E. Perez (2009)
Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies.Cancer Research, 69
K. Gelmon (2011)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialBreast Diseases: A Year Book Quarterly, 22
Bianca Verbeek, T. Vroom, S. Adriaansen‐slot, Astrid Ottenhoff-Kalff, J. Geertzema, A. Hennipman, G. Rijksen (1996)
c‐Src PROTEIN EXPRESSION IS INCREASED IN HUMAN BREAST CANCER. AN IMMUNOHISTOCHEMICAL AND BIOCHEMICAL ANALYSISThe Journal of Pathology, 180
S. Hiscox, L. Morgan, T. Green, D. Barrow, J. Gee, R. Nicholson (2006)
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cellsBreast Cancer Research and Treatment, 97
Leo Niemeier, D. Dabbs, S. Beriwal, Joan Striebel, R. Bhargava (2010)
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiationModern Pathology, 23
T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka, T. Mierzwa, M. Szwiec, R. Wiśniowski, M. Siołek, R. Dent, J. Lubiński, S. Narod (2010)
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 3
D. Silver, A. Richardson, A. Eklund, Z. Wang, Z. Szallasi, Qiyuan Li, N. Juul, C. Leong, Diana Calogrias, Ayodele Buraimoh, Aquila Fatima, R. Gelman, P. Ryan, N. Tung, A. Nicolo, S. Ganesan, A. Miron, C. Colín, D. Sgroi, L. Ellisen, E. Winer, J. Garber (2010)
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
P. Boström, M. Söderström, Tuire Palokangas, T. Vahlberg, Y. Collan, O. Carpén, P. Hirsimäki (2009)
Analysis of cyclins A, B1, D1 and E in breast cancer in relation to tumour grade and other prognostic factorsBMC Research Notes, 2
M. Audeh, J. Carmichael, R. Penson, M. Friedlander, B. Powell, K. Bell-McGuinn, C. Scott, J. Weitzel, A. Oaknin, N. Loman, K. Lu, R. Schmutzler, U. Matulonis, M. Wickens, A. Tutt (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialThe Lancet, 376
R. Rouzier, C. Perou, W. Symmans, N. Ibrahim, M. Cristofanilli, K. Anderson, K. Hess, J. Stec, J. Stec, M. Ayers, P. Wagner, P. Morandi, Chang Fan, Islam Rabiul, J. Ross, G. Hortobagyi, L. Pusztai (2005)
Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 11
J. Lehmann-Che, F. André, C. Desmedt, C. Mazouni, S. Giacchetti, E. Turpin, M. Espié, L. Plassa, M. Marty, P. Bertheau, C. Sotiriou, M. Piccart, W. Symmans, L. Pusztai, H. Thé (2010)
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.The oncologist, 15 3
F. André, B. Job, P. Dessen, A. Tordai, S. Michiels, C. Liedtke, C. Richon, Kai Yan, Bailang Wang, G. Vassal, S. Delaloge, G. Hortobagyi, W. Symmans, V. Lazar, L. Pusztai (2009)
Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization ArrayClinical Cancer Research, 15
S. Scholl, J. Pierga, B. Asselain, P. Beuzeboc, T. Dorval, E. Garcia-Giralt, M. Jouve, T. Palangié, Y. Remvikos, J. Durand, A. Fourquet, P. Pouillart (1995)
Breast tumour response to primary chemotherapy predicts local and distant control as well as survival.European journal of cancer, 31A 12
S. Isakoff, B. Overmoyer, N. Tung, R. Gelman, V. Giranda, K. Bernhard, K. Habin, L. Ellisen, E. Winer, P. Goss (2010)
A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.Journal of Clinical Oncology, 28
F. Geyer, M. Lacroix-Triki, K. Savage, M. Arnedos, M. Lambros, A. Mackay, R. Natrajan, J. Reis-Filho (2011)
β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutationModern Pathology, 24
R. Dent, W. Hanna, M. Trudeau, E. Rawlinson, P. Sun, S. Narod (2009)
Pattern of metastatic spread in triple-negative breast cancerBreast Cancer Research and Treatment, 115
C. Barrios, M. Liu, S. Lee, L. Vanlemmens, J. Ferrero, T. Tabei, X. Pivot, H. Iwata, K. Aogi, Marla Brickman, K. Zhang, K. Kern, Miguel Martín (2009)
Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC).Cancer Research, 69
M. Cheang, D. Voduc, C. Bajdik, S. Leung, S. McKinney, S. Chia, C. Perou, T. Nielsen (2008)
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative PhenotypeClinical Cancer Research, 14
Shusen Wang, Yanxia Shi, Zhongyu Yuan, Xi Wang, Donggeng Liu, Roujun Peng, Xiao-yu Teng, T. Qin, Jiewen Peng, G. Lin, Xiaomei Jiang (2012)
Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimensMedical Oncology, 29
(2010)
FinXX final 5-year analysis: results
F. Sapunar, I. Smith (2000)
Neoadjuvant chemotherapy for breast cancerAnnals of Medicine, 32
J. Pippen, D. Paul, C. Stokoe, J. Blum, L. Krekow, F. Holmes, D. Lindquist, S. Sedlacek, R. Rivera, R. Brooks, S. Vukelja, K. McIntyre, C. Lopez-Diaz, J. O’Shaughnessy (2011)
Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
J. O’Shaughnessy, V. Diéras, J. Glaspy, A. Brufsky, K. Miller, D. Miles, P. Koralewski, S. Phan, S. Bhattacharya (2009)
Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC).Cancer Research, 69
M. Arnedos, J. Cruz, B. Job, V. Scott, P. Dessen, D. Gentien, S. Roman-Roman, S. Delaloge, V. Lazar, F. André (2011)
801 ORAL High Throughput Molecular Analyses to Select Patients for Targeted AgentsEuropean Journal of Cancer, 47
B. Lehmann, Joshua Bauer, X. Chen, M. Sanders, A. Chakravarthy, Y. Shyr, J. Pietenpol (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.The Journal of clinical investigation, 121 7
J. Hugh, J. Hanson, M. Cheang, T. Nielsen, C. Perou, C. Dumontet, J. Reed, M. Krajewska, I. Treilleux, M. Rupin, E. Magherini, J. Mackey, Miguel Martín, C. Vogel (2009)
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 8
K. Gelmon, A. Chan, N. Harbeck (2006)
The role of capecitabine in first-line treatment for patients with metastatic breast cancer.The oncologist, 11 Suppl 1
C. Perou, T. Sørlie, M. Eisen, M. Rijn, S. Jeffrey, Christian Rees, J. Pollack, D. Ross, H. Johnsen, L. Akslen, Ø. Fluge, Alexander Pergamenschikov, Cheryl Williams, Shirley Zhu, P. Lønning, A. Børresen-Dale, P. Brown, D. Botstein (2000)
Molecular portraits of human breast tumoursNature, 406
Ling-Zhi Liu, Xiang-dong Zhou, G. Qian, Xianglin Shi, Jing Fang, B. Jiang (2007)
AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway.Cancer research, 67 13
K. Tedesco, J. Blum, A. Gonçalves, J. Lubiński, N. Ben-Baruch, C. Osborne, P. Lardelli, J. Tercero, F. Holmes, S. Delaloge (2010)
A phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC).Journal of Clinical Oncology, 28
(2009)
damaged induced apoptosis through inhibition
G. Minckwitz, H. Eidtmann, M. Rezai, P. Fasching, H. Tesch, H. Eggemann, I. Schrader, K. Kittel, C. Hanusch, R. Kreienberg, C. Solbach, B. Gerber, C. Jackisch, G. Kunz, J. Blohmer, J. Huober, M. Hauschild, T. Fehm, B. Müller, C. Denkert, S. Loibl, V. Nekljudova, M. Untch (2012)
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.The New England journal of medicine, 366 4
W. Gradishar, V. Kaklamani, T. Sahoo, D. Lokanatha, V. Raina, S. Bondarde, M. Jain (2009)
A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).Cancer Research, 69
L. Carey, E. Dees, L. Sawyer, Lisa Gatti, D. Moore, F. Collichio, D. Ollila, C. Sartor, M. Graham, C. Perou (2007)
The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 13
K. Miller, Molin Wang, J. Gralow, M. Dickler, M. Cobleigh, E. Perez, T. Shenkier, D. Cella, N. Davidson (2007)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.The New England journal of medicine, 357 26
C. Liedtke, C. Mazouni, K. Hess, F. André, A. Tordai, J. Mejia, W. Symmans, A. González-Angulo, B. Hennessy, Marjorie Green, M. Cristofanilli, G. Hortobagyi, L. Pusztai (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 8
S. Mabuchi, C. Kawase, D. Altomare, K. Morishige, Kenjiro Sawada, M. Hayashi, M. Tsujimoto, M. Yamoto, Andres Klein-Szanto, R. Schilder, M. Ohmichi, J. Testa, T. Kimura (2009)
mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the OvaryClinical Cancer Research, 15
J. O’Shaughnessy, C. Osborne, J. Pippen, M. Yoffe, D. Patt, C. Rocha, I. Koo, B. Sherman, C. Bradley (2011)
Iniparib plus chemotherapy in metastatic triple-negative breast cancer.The New England journal of medicine, 364 3
A. Brufsky, I. Bondarenko, V. Smirnov, S. Hurvitz, E. Perez, O. Ponomarova, I. Vynnychenko, R. Swamy, H. Mu, R. Rivera (2009)
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.Cancer Research, 69
C. Falo, A. Moreno, M. Varela, B. Lloveras, A. Figueras, A. Escobedo (2007)
HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapyJournal of Cancer Research and Clinical Oncology, 133
A. Doane, M. Danso, P. Lal, M. Donaton, Liguo Zhang, C. Hudis, W. Gerald (2006)
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgenOncogene, 25
E. Perez, T. Patel, A. Moreno-Aspitia (2010)
Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancerBreast Cancer Research and Treatment, 121
S. Zabludoff, C. Deng, M. Grondine, A. Sheehy, S. Ashwell, B. Caleb, S. Green, H. Haye, C. Horn, J. Janetka, Dongfang Liu, E. Mouchet, Shannon Ready, J. Rosenthal, C. Quéva, G. Schwartz, K. Taylor, A. Tse, G. Walker, A. White (2008)
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapiesMolecular Cancer Therapeutics, 7
J. O’Shaughnessy, D. Paul, C. Stokoe, J. Pippen, J. Blum, L. Krekow, F. Holmes, S. Vukelja, D. Lindquist, S. Sedlacek, R. Rivera, R. Brooks, K. McIntyre, R. Pluenneke, J. Schwartz, Stephen Jones, C. Brownstein, F. Gilberg (2010)
Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast CancerCancer Research, 70
A. Brufsky, S. Hurvitz, E. Perez, R. Swamy, V. Valero, V. O'Neill, H. Rugo (2011)
RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 32
J. Mahany, N. Lewis, E. Heath, P. LoRusso, M. Mita, J. Rodón, A. Tolcher, B. Sherman, C. Bradley, K. Papadopoulos (2008)
A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumorsJournal of Clinical Oncology, 26
E. Rakha, M. El-Sayed, A. Green, Andrew Lee, J. Robertson, I. Ellis (2007)
Prognostic markers in triple‐negative breast cancerCancer, 109
H. Farmer, N. Mccabe, C. Lord, A. Tutt, Damian Johnson, T. Richardson, M. Santarosa, Krystyna Dillon, I. Hickson, C. Knights, N. Martin, S. Jackson, G. Smith, A. Ashworth (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 434
B. Marty, V. Maire, E. Gravier, G. Rigaill, A. Vincent-Salomon, Marion Kappler, I. Lebigot, Fathia Djelti, Audrey Tourdès, P. Gestraud, P. Hupé, E. Barillot, F. Cruzalegui, G. Tucker, M. Stern, J. Thiery, J. Hickman, T. Dubois (2008)
Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cellsBreast Cancer Research : BCR, 10
J. O’Shaughnessy, Lee Schwartzberg, M. Danso, H. Rugo, K. Miller, D. Yardley, Robert Carlson, R. Finn, Eric Charpentier, M. Freese, Sanjay Gupta, A. Blackwood-Chirchir, E. Winer (2011)
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
H. Roché, P. Fumoleau, M. Spielmann, J. Canon, T. Delozier, D. Serin, M. Symann, P. Kerbrat, P. Soulié, F. Eichler, P. Viens, A. Monnier, A. Vindevoghel, M. Campone, M. Goudier, J. Bonneterre, J. Ferrero, Anne-Laure Martin, J. Genève, B. Asselain (2006)
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 36
S. Azoulay, M. Laé, P. Fréneaux, S. Merle, A. Ghuzlan, Caroline Chnecker, C. Rosty, J. Klijanienko, B. Sigal‐Zafrani, R. Salmon, A. Fourquet, X. Sastre-Garau, A. Vincent-Salomon (2005)
KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcomeModern Pathology, 18
N. Turner, A. Tutt, A. Ashworth (2004)
Hallmarks of 'BRCAness' in sporadic cancersNature Reviews Cancer, 4
L. Vahdat, L. Fein, M. Karwal, M. Campone, R. Peck, P. Mukhopadhyay, J. Jassem (2009)
Ixabepilone plus capecitabine vs capecitabine in patients with metastatic breast cancer receiving ixabepilone in the first line setting: a pooled analysis from two phase III studies.Cancer Research, 69
S. Kopetz, M. Mita, Isabel Mok, K. Sankhala, Jennifer Moseley, B. Sherman, C. Bradley, A. Tolcher (2008)
First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumorsJournal of Clinical Oncology, 26
J. Dungan (2011)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trialYearbook of Obstetrics, Gynecology and Women's Health, 2011
S. Ashwell, J. Janetka, S. Zabludoff (2008)
Keeping checkpoint kinases in line: new selective inhibitors in clinical trials.Expert opinion on investigational drugs, 17 9
S. Park, H. Lee, Hailun Li, M. Shipitsin, R. Gelman, K. Polyak (2010)
Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast CancerClinical Cancer Research, 16
B. Linderholm, H. Hellborg, U. Johansson, G. Elmberger, L. Skoog, J. Lehtiö, R. Lewensohn (2009)
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 20 10
Iwan Beuvink, A. Boulay, S. Fumagalli, Frédéric Zilbermann, S. Ruetz, T. O'reilly, F. Natt, Jonathan Hall, H. Lane, G. Thomas (2005)
The mTOR Inhibitor RAD001 Sensitizes Tumor Cells to DNA-Damaged Induced Apoptosis through Inhibition of p21 TranslationCell, 120
The so-called triple-negative breast cancer, as defined by tumors that lack estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2) overexpression, has generated growing interest in recent years despite representing less than 20% of all breast cancers. These tumors constitute an important clinical challenge, as they do not respond to endocrine treatment and other targeted therapies. As a group they harbor an aggressive clinical phenotype with early development of visceral metastases and a poor long-term prognosis. While chemotherapy remains effective in triple-negative disease, research continues to further identify potential new targets based on phenotypical and molecular characteristics of these tumors. In this respect, the presence of a higher expression of different biomarkers including epidermal growth factor receptor, vascular endothelial growth factor receptor, fibroblast growth factor receptor and Akt activation has led to a proliferation of clinical trials assessing the role of inhibitors to these pathways in triple-negative tumors. Moreover, the described overlap between triple-negative and basal-like tumors, and the similarities with tumors arising in the BRCA1 mutation carriers has offered potential therapeutic avenues for patients with these cancers including poly (ADP-ribose) polymerase inhibitors and a focus on a higher sensitivity to alkylating chemotherapy agents. Results from these trials have shown some benefit in small subgroups of patients, even in single-agent therapy, which reflects the heterogeneity of triple-negative breast cancer and highlights the need for a further subclassification of these types of tumors for better prognosis identification and treatment individualization.
Therapeutic Advances in Medical Oncology – SAGE
Published: Apr 30, 2012
Keywords: basal-like,BRCA1,breast cancer,PARP,poly(ADP-ribose) polymerase inhibitors,triple negative
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.